NEW YORK, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Zai Lab Ltd. (Nasdaq: ZLAB ), a biopharmaceutical company based in Shanghai focused on bringing transformative medicines to patients in China and around the world, rang the opening bell at the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/Attachm...f5af48e496
http://www.globenewswire.com/NewsRoom/Attachm...c3db428fd4
Zai Lab focuses on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases. The company aims to foster innovation by addressing these unmet needs and leveraging underutilized resources in China. Since their founding in 2014, they have assembled an innovative pipeline consisting of six drug candidates through partnerships with global biopharmaceutical companies. In the long term, they plan to build a premier, fully integrated drug discovery and development platform that brings both in-licensed and internally-discovered medicines to patients in China and globally.
“Zai Lab has an extensive track record of developing innovative drugs in China,” said Nelson Griggs, President of the Nasdaq Stock Exchange. “They are able to leverage their resources and expertise in order to meet the expanding needs of the biopharmaceutical industry. We are extremely proud to be their partner throughout their journey as they transform human health services worldwide.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq Nasdaq (Nasdaq: NDAQ ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
About Zai Lab Zai Lab (NASDAQ: ZLAB ) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partner’s and its own products in order to impact human health worldwide.
For more information, please visit www.zailaboratory.com
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com
Emily Pan (646) 441-5120 emily.pan@nasdaq.com
- NDAQG -
